Jazz Pharmaceuticals (FRA:J7Z) Institutional Ownership: 77.40% (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J7Z Jazz Pharmaceuticals PLC FRA:J7Z
74 GF Score
Price €210.20
GF Value €130.60
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Institutional Ownership?

Jazz Pharmaceuticals FRA:J7Z -0.94% 74 Institutional Ownership is 77.40% as of Aug. 15, 2026. GuruFocus rates FRA:J7Z with a GF Score™ of 74/100 and a GF Value™ of €130.60 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Jazz Pharmaceuticals's institutional ownership is 77.40%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Jazz Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Jazz Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 97.15%.

Jazz Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Institutional Ownership Chart

Jazz Pharmaceuticals Historical Data

The historical data trend for Jazz Pharmaceuticals can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 73.38 74.96 74.96 74.93 75.57 76.38 77.11 78.21 76.70 77.40
FRA:J7Z
74GF Score
Jazz Pharmaceuticals PLC FRA:J7Z
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 77.40% mean?
Jazz Pharmaceuticals (FRA:J7Z) has a Institutional Ownership of 77.40% as of Aug. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Institutional Ownership too high?
Jazz Pharmaceuticals' current Institutional Ownership is 77.40%. Overall, Jazz Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Institutional Ownership compare to BBIO and ASND?
Jazz Pharmaceuticals' Institutional Ownership of 77.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Institutional Ownership is 77.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €130.60, compared to a current price of €210.20 — trading 60.9% above its estimated fair value. The current Institutional Ownership is 77.40%. Jazz Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current Institutional Ownership is 77.40% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €210.20 is trading 60.9% above its estimated GF Value™ of €130.60. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:J7Z:

  • Institutional Ownership: 77.40%
  • GF Value™: €130.60 vs. price of €210.20 (60.9% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
74GF Score

Get the complete analysis for FRA:J7Z

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€210.20
Price
€130.60
GF Value